Home / Current Issue / Paper 1725434
An Examination of Innovative Drug Strategies to Address Multidrug-Resistant Bacterial Infections
Subject area: Biological & Medical Sciences · Area of research: Multidrug-Resistant Bacterial Infections
Abstract
Infections due to multidrug-resistant (MDR) bacteria present a major challenge to modern healthcare since resistance can weaken the effectiveness of multiple antibiotic classes, resulting in greater complexity, length, and cost of treatment. Resistance develops through mechanisms such as enzymes that deactivate antibiotics, altered drug targets, reduced membrane permeability, active efflux, metabolic changes, and biofilm creation. This review examines new pharmacological strategies aimed at preventing, addressing, or improving conventional antibacterial therapies. It includes the latest combinations of β-lactam/β-lactamase inhibitors, antibiotics associated with siderophores, substances aimed at resistant Acinetobacter, antimicrobial peptides, phage therapy, anti-virulence substances, techniques to break down biofilms, antibiotic boosters, immunotherapy approaches, and CRISPR-based antimicrobials. Examples include cefiderocol, ceftazidime-avibactam, aztreonam-avibactam, and durlobactam-sulbactam.
Keywords
multidrug resistance, resistance to antimicrobials, innovative antibiotics, β-lactamase inhibitors, bacteriophage treatment, biofilm, adjuvants for antibiotics
References
[1] Giurazza R, Mazza MC, Andini R, Sansone P, Pace MC, Durante-Mangoni E. Emerging treatment options for multi-drug-resistant bacterial infections. Life (Basel). 2021;11(6):519. https://doi.org/10.3390/life11060519
[2] Vitiello A, Rezza G, Silenzi A, Salzano A, Alise M, Boccellino MR, et al. Therapeutic strategies to combat increasing rates of multidrug resistant pathogens. Pharm Res. 2024;41(8):1557–71. https://doi.org/10.1007/s11095-024-03756-5
[3] Jacobowski AC, Boleti APA, Cruz MV, Santos KFDP, Andrade LRM, Frihling BEF, et al. Combating antimicrobial resistance: innovative strategies using peptides, nanotechnology, phages, quorum sensing interference, and CRISPR-Cas systems. Pharmaceuticals (Basel). 2025;18(8):1119. https://doi.org/10.3390/ph18081119
[4] Rathored J, Budhbaware T. Integrative strategies against multidrug-resistant bacteria: synthesizing novel antimicrobial frontiers for global health. Microb Pathog. 2025;208:108018. https://doi.org/10.1016/j.micpath.2025.108018
[5] Geng S, Tang Q, Shi N. Antibiotic-sparing strategies for multidrug-resistant organism (MDRO) infections. Front Pharmacol. 2025;16:1653424. https://doi.org/10.3389/fphar.2025.1653424
[6] Vázquez-López R, et al. A comprehensive overview of antibacterial agents for combating multidrug-resistant bacteria: the current landscape, development, future opportunities, and challenges. Antibiotics (Basel). 2025;14(3):221. https://doi.org/10.3390/antibiotics14030221
[7] Novel antibacterial approaches and therapeutic strategies. Antibiotics (Basel). 2025;14(4):404. https://doi.org/10.3390/antibiotics14040404
[8] Imran M, Ahmad MN, Dasgupta A, Rana P, Srinivas N, Chopra S. Novel approaches for the treatment of infections due to multidrug-resistant bacterial pathogens. Future Med Chem. 2022;14(15):1133–48. https://doi.org/10.4155/fmc-2022-0029
[9] El-Sayed SE, Messiha AA, Zafer M. Effective alternative strategies to combat challenges associated with MDR bacterial infections: drug repurposing, role of artificial intelligence, and novel therapeutic options. J Infect Public Health. 2026;19(2):103058. https://doi.org/10.1016/j.jiph.2025.103058
[10] Acharya A, Singh AK, Tiwari S, Kaushal B, Ghosh J, Kumar A, et al. Combatting antibiotic resistance: challenges and emerging therapeutic strategies. Future Microbiol. 2026;21(1):87–103. https://doi.org/10.1080/17460913.2026.2627823
[11] Peng H, Chen IA, Qimron U. Engineering phages to fight multidrug-resistant bacteria. Chem Rev. 2025;125(2):933–71. https://doi.org/10.1021/acs.chemrev.4c00681
[12] Abdelkader K, Gerstmans H, Saafan A, De Vos D, Briers Y. The preclinical and clinical progress of bacteriophages and their lytic enzymes: the parts are easier than the whole. Viruses. 2019;11(2):96. https://doi.org/10.3390/v11020096
[13] Bhale B, Shirodkar S, Sawarkar S, Omri A. Phage therapy: innovations, challenges, and future directions in combating superbugs and antibiotic resistance. Expert Rev Anti Infect Ther. 2026;24(2):213–37. https://doi.org/10.1080/14787210.2026.2632669
[14] Alzahrani AJ. Bacteriophage therapy against multidrug resistant bacterial infections demonstrates clinical advances and engineering innovations between 2020–2026. Front Microbiol. 2026;17:1865548. https://doi.org/10.3389/fmicb.2026.1865548
[15] Sahu P, Satapathy T. Beyond new pills: integrative strategies to overcome multidrug-resistant bacteria. Arch Microbiol. 2026;208(6). https://doi.org/10.1007/s00203-026-04817-6
[16] Yan B, Yan C, Ding Y, Cai S, Wang Y, Agbo E, et al. Multidrug-resistant Pseudomonas aeruginosa infections: current status, challenges, and prospects of phage therapy. Front Microbiol. 2026;16:1723885. https://doi.org/10.3389/fmicb.2025.1723885
[17] Piracha ZZ, Saeed U. Next-generation bacteriophage therapeutic systems: CRISPR-based engineering, near-infrared bioimaging, and precision strategies for treating multidrug-resistant and extensively drug-resistant bacterial infections. Front Microbiol. 2026. https://doi.org/10.3389/fmicb.2026.1748742
[18] Innovative strategies in the fight against bacterial infections: phage therapy, nanotechnology, and new antimicrobial agents for multidrug-resistant pathogens. Results Chem. 2025;15:102304. https://doi.org/10.1016/j.rechem.2025.102304
[19] Combating antibiotic resistance: mechanisms, multidrug-resistant pathogens, and novel therapeutic approaches: an updated review. Pharmaceuticals (Basel). 2025;18(3):402. https://doi.org/10.3390/ph18030402
[20] Effective alternative strategies to combat challenges associated with MDR bacterial infections: drug repurposing, role of artificial intelligence, and novel therapeutic options. J Infect Public Health. 2026;19(2):103058. https://doi.org/10.1016/j.jiph.2025.103058
[21] Machado E, Sousa JC. New antibiotics for treating infections caused by multidrug-resistant bacteria. Antibiotics (Basel). 2025;14(10):997. https://doi.org/10.3390/antibiotics14100997
[22] Tängdén T, Carrara E, Hellou MM, Yahav D, Paul M. Introducing new antibiotics for multidrug-resistant bacteria: obstacles and the way forward. Clin Microbiol Infect. 2025. https://doi.org/10.1016/j.cmi.2024.09.025
[23] Windham S, Kollef MH. How to use new antibiotics in the therapy of serious multidrug resistant Gram-negative infections? Curr Opin Infect Dis. 2022;35(6):561–7. https://doi.org/10.1097/QCO.0000000000000858
[24] Macesic N, Uhlemann AC, Peleg AY. Multidrug-resistant Gram-negative bacterial infections. Lancet. 2025;405(10474):257–72. https://doi.org/10.1016/S0140-6736(24)02081-6
[25] Delroba K, Alaei M, Khalili H. Treatment options for infections caused by multidrug-resistant Gram-negative bacteria: a guide to good clinical practice. Future Microbiol. 2023;18:287–94. https://doi.org/10.2217/fmb-2022-0160
[26] Jhalora V, Bist R. A comprehensive review of molecular mechanisms leading to the emergence of multidrug resistance in bacteria. Indian J Microbiol. 2025;65(2):844–65. https://doi.org/10.1007/s12088-024-01384-6
[27] Birlutiu V, Birlutiu RM. An overview of the epidemiology of multidrug resistance and bacterial resistance mechanisms: what solutions are available? A comprehensive review. Microorganisms. 2025;13(9):2194. https://doi.org/10.3390/microorganisms13092194
[28] Temesgen AB, Shiferaw SA. Antimicrobial multidrug resistance and mechanisms of action: an overview. Biomed Res Int. 2025;2025:8847267. https://doi.org/10.1155/bmri/8847267
[29] Elshobary ME, Badawy NK, Ashraf Y, Zatioun AA, Masriya HH, Ammar MM, et al. Combating antibiotic resistance: mechanisms, multidrug-resistant pathogens, and novel therapeutic approaches: an updated review. Pharmaceuticals (Basel). 2025;18(3):402. https://doi.org/10.3390/ph18030402
[30] Phages as antimicrobials against multi-drug resistant bacteria. Front Microbiol. 2026;17:1747240. https://doi.org/10.3389/fmicb.2026.1747240
How to cite this paper
@article{1725434,
author = {R Thelshath, G Sridhar, V Kalaivani, K Vinoth, A Srigopivarshini; R.Vishalatchi; S.Vishnupriya; P.Yuvaraj},
title = {An Examination of Innovative Drug Strategies to Address Multidrug-Resistant Bacterial Infections},
journal = {Iconic Research And Engineering Journals},
year = {2026},
volume = {10},
number = {5},
pages = {4604-4614},
issn = {2456-8880},
url = {https://www.irejournals.com/formatedpaper/1725434.pdf},
abstract = {Infections due to multidrug-resistant (MDR) bacteria present a major challenge to modern healthcare since resistance can weaken the effectiveness of multiple antibiotic classes, resulting in greater complexity, length, and cost of treatment. Resistance develops through mechanisms such as enzymes that deactivate antibiotics, altered drug targets, reduced membrane permeability, active efflux, metabolic changes, and biofilm creation. This review examines new pharmacological strategies aimed at preventing, addressing, or improving conventional antibacterial therapies. It includes the latest combinations of β-lactam/β-lactamase inhibitors, antibiotics associated with siderophores, substances aimed at resistant Acinetobacter, antimicrobial peptides, phage therapy, anti-virulence substances, techniques to break down biofilms, antibiotic boosters, immunotherapy approaches, and CRISPR-based antimicrobials. Examples include cefiderocol, ceftazidime-avibactam, aztreonam-avibactam, and durlobactam-sulbactam.},
keywords = {multidrug resistance, resistance to antimicrobials, innovative antibiotics, β-lactamase inhibitors, bacteriophage treatment, biofilm, adjuvants for antibiotics},
month = {November},
}